Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2824-2833

  Holloway, Georgina A ^a   Charman, William N ^b   Fairlamb, Alan H ^c   Brun, Reto ^d   Kaiser, Marcel ^d   Kostewicz, Edmund ^b   Novello, Patrizia M ^a   Parisot, John P ^a   Richardson, John ^b   Street, Ian P ^a   Watson, Keith G ^a   Baell, Jonathan B ^a,e  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZINE DERIVATIVE; ANTIPARASITIC AGENT; BENZHYDRYL DERIVATIIVE; ENZYME INHIBITOR; HETEROCYCLIC COMPOUND; IMINOBENZIMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TRYPANOTHIONE REDUCTASE; TRYPANOTHIONE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PHOTOMETRY; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPARASITIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NADH, NADPH OXIDOREDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOSOMA; TRYPANOSOMIASIS;

EID: 67650003698     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01568-08     Document Type: Article

References (54)

1. Augustyns, K., K. Amssoms, A. Yamani, P. K. Rajan, and A. Haemers. 2001. Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Curr. Pharm. Des. 7:1117-1141.
2. Bailey, S., K. Smith, A. H. Fairlamb, and W. N. Hunter. 1993. Substrate interactions between trypanothione reductase and N1- glutathionylspermidine disulphide at 0.28-nm resolution. Eur. J. Biochem. 213:67-75.
3. Berman, J., A. D. M. Bryceson, S. Croft, J. Engel, W. Gutteridge, J. Karbwang, H. Sindermann, J. Soto, S. Sundar, and J. A. Urbina. 2006. Miltefosine: issues to be addressed in the future. Trans. R. Soc. Trop. Med. Hyg. 100:S41-S44.
4. Berman, J. D. 2006. Development of miltefosine for the leishmaniases. Mini Rev. Med. Chem. 6:145-151.
5. Bevan, C. D., and R. S. Lloyd. 2000. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72:1781-1787.
6. Bond, C. S., Y. Zhang, M. Berriman, M. L. Cunningham, A. H. Fairlamb, and W. N. Hunter. 1999. Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure (London) 7:81-89.
7. Borges, A., M. L. Cunningham, J. Tovar, and A. H. Fairlamb. 1995. Sitedirected mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase. Eur. J. Biochem. 228:745-752.
8. Buckner, F. S., C. L. M. J. Verlinde, A. C. la Flamme, and W. C. van Voorhis. 1996. Efficient technique for screening drugs for activity against Trypanosma cruzi using parasites expressing -galactosidase. Antimicrob. Agents Chemother. 40:2592-2597.
9. Burri, C., S. Bernhard, C. Olson, A. Mpanya Kabeya, J. P. Fina Lubaki, and G. Pohlig. 2007. Phase III trial of pafuramidine maleate (DB289), a novel, oral drug for treatment of first stage sleeping sickness, poster P1.16. R. Soc. Trop. Med. Hyg. Centenary Conf., London, United Kingdom.
10. Cammerer, S. B., C. J. S. Jimenez, L. Gros, S. O. Lorente, C. Rodrigues, J. C. F. Rodrigues, A. Caldera, L. M. R. Perez, W. da Souza, M. Kaiser, R. Brun, J. A. Urbina, D. G. Pacanowska, and I. H. Gilbert. 2007. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother. 51: 4049-4061.
11. Croft, S. L., S. Sundar, and A. H. Fairlamb. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
12. Cunningham, I. 1977. New culture medium for maintenance of tsetse tissues and growth of trypanosomatids. J. Protozool. 24:325-329.
13. Czechowicz, J. A., A. K. Wilhelm, M. D. Spalding, A. M. Larson, L. K. Engel, and D. G. Alberg. 2007. The synthesis and inhibitory activity of dethiotrypanothione and analogues against trypanothione reductase. J. Org. Chem. 72:3689-3693.
14. Delespaux, V., and H. P. de Koning. 2007. Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat. 10:30-50.
15. Dumas, C., M. Ouellette, J. Tovar, M. L. Cunningham, A. H. Fairlamb, S. Tamar, M. Olivier, and B. Papadopoulou. 1997. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J. 16:2590-2598.
16. Edwards, J. P., L. Zhi, C. L. F. Pooley, C. M. Tegley, S. J. West, M.-W. Wang, M. M. Gottardis, C. Pathirana, W. T. Schrader, and T. K. Jones. 1998. Preparation, resolution, and biological evaluation of 5-aryl-1,2-dihydro- 5Hchromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. J. Med. Chem. 41:2779-2785.
17. Fairlamb, A. H., P. Blackburn, P. Ulrich, B. T. Chait, and A. Cerami. 1985. Trypanothione: a novel bis(glutathionyl)spermidine cofactor of glutathione reductase in trypanosomatids. Science 227:1485-1487.
18. Gallwitz, H., S. Bonse, A. Martinez-Cruz, I. Schlichting, K. Schumacher, and R. L. Krauth-Siegel. 1999. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. J. Med. Chem. 42:364-372.
19. Garforth, J., H. Yin, J. H. McKie, K. T. Douglas, and A. H. Fairlamb. 1997. Rational design of selective ligands for trypanothione reductase from Trypanosoma cruzi. Structural effects on the inhibition by dibenzazepines based on imipramine. J. Enzyme Inhib. 12:161-173.
20. Girault, S., E. Davioud-Charvet, L. Maes, J.-F. Dubremetz, M.-A. Debreu, V. Landry, and C. Sergheraert. 2001. Potent and specific inhibitors of trypanothione reductase from Trypanosoma cruzi: bis(2- aminodiphenylsulfides) for fluorescent labeling studies. Bioorg. Med. Chem. 9:837-846.
21. Guedes, P. M. M., J. L. R. Fietto, M. Lana, and M. T. Bahia. 2006. Advances in Chagas disease chemotherapy. Anti-Infect. Agents Med. Chem. 5:175-186.
22. Hamilton, C. J., A. Saravanamuthu, I. M. Eggleston, and A. H. Fairlamb. 2003. Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochem. J. 369:529-537.
23. Holloway, G. A., J. B. Baell, A. H. Fairlamb, P. M. Novello, J. P. Parisot, J. Richardson, K. G. Watson, and I. P. Street. 2007. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitors by high-throughput chemical screening. Bioorg. Med. Chem. Lett. 17:1422-1427.
24. Hunter, W. N., S. Bailey, J. Habash, S. J. Harrop, J. R. Helliwell, T. Aboagye-Kwarteng, K. Smith, and A. H. Fairlamb. 1992. Active site of trypanothione reductase. A target for rational drug design. J. Mol. Biol. 227:322-333.
25. Jacoby, E. M., I. Schlichting, C. B. Lantwin, W. Kabsch, and R. L. Krauth-Siegel. 1996. Crystal structure of the Trypanosoma cruzi trypanothione reductase mepacrine complex. Proteins 24:73-80.
26. Klempner, M. S., T. R. Unnasch, and L. T. Hu. 2007. Taking a bite out of vector-transmitted infectious diseases. N. Engl. J. Med. 356:2567-2569.
27. 3 antagonists. Bioorg. Med. Chem. 11:1319-1341.
28. Krauth-Siegel, R. L., H. Bauer, and R. H. Schirmer. 2005. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew. Chem. Int. Ed. Engl. 44:690-715.
29. Krauth-Siegel, R. L., S. K. Meiering, and H. Schmidt. 2003. The parasitespecific trypanothione metabolism of Trypanosoma and Leishmania. Biol. Chem. 384:539-549.
30. Krauth-Siegel, R. L., C. Sticherling, I. Jöst, C. T. Walsh, E. F. Pai, W. Kabsch, and C. B. Lantwin. 1993. Crystallization and preliminary crystallographic analysis of trypanothione reductase from Trypanosoma cruzi, the causative agent of Chagas' disease. FEBS Lett. 317:105-108.
31. Krieger, S., W. Schwarz, M. R. Ariyanayagam, A. H. Fairlamb, R. L. Krauth-Siegel, and C. Clayton. 2000. Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35:542-552.
32. Li, Z., M. W. Fennie, B. Ganem, M. T. Hancock, M. Kobaslija, D. Rattendi, C. J. Bacchi, and M. C. O'Sullivan. 2001. Polyamines with N-(3-phenylpropyl) substituents are effective competitive inhibitors of trypanothione reductase and trypanocidal agents. Bioorg. Med. Chem. Lett. 11:251-254.
33. Liñares, G. E. G., E. L. Ravaschino, and J. B. Rodriguez. 2006. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr. Med. Chem. 13:335-360.
34. Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
35. Lombardo, F., M. Shalaeva, K. A. Tupper, and F. Gao. 2001. ElogDoct: a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J. Med. Chem. 44:2490-2497.
36. Marsh, I. R., and M. Bradley. 1997. Substrate specificity of trypanothione reductase. Eur. J. Biochem. 243:690-694.
37. McGovern, S. L., E. Caselli, N. Grigorieff, and B. K. Shoichet. 2002. A common mechanism underlying promiscuous inhibitors from virtual highthroughput screening. J. Med. Chem. 45:1712-1722.
38. Oprea, T. I., A. M. Davis, S. J. Teague, and P. D. Leeson. 2001. Is there a difference between leads and drugs? A historical perspective. J. Chem. Infect. Comput. Sci. 41:1308-1315.
39. O'Sullivan, M. C. 2005. The battle against trypanosomiasis and leishmaniasis: metal-based and natural product inhibitors of trypanothione reductase. Curr. Med. Chem. Anti-Infect. Agents 4:355-378.
40. Otero, L., M. Vieites, L. Boiani, A. Denicola, C. Rigol, L. Opazo, C. Olea-Azar, J. D. Maya, A. Morello, R. L. Krauth-Siegel, O. E. Piro, E. Castellano, M. Gonzalez, D. Gambino, and H. Cerecetto. 2006. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J. Med. Chem. 49: 3322-3331.
41. Parveen, S., M. O. F. Khan, S. E. Austin, S. L. Croft, V. Yardley, P. Rock, and K. T. Douglas. 2005. Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. J. Med. Chem. 48: 8087-8097.
42. Paulino, M., F. Iribarne, M. Dubin, S. Aguilera-Morales, O. Tapia, and A. O. M. Stoppani. 2005. The chemotherapy of Chagas' disease: an overview. Mini Rev. Med. Chem. 5:499-519.
43. Priotto, G., S. Kasparian, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, and U. Karunakara. 2007. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin. Infect. Dis. 45:1435-1442.
44. Schmidt, A., and R. Krauth-Siegel. 2002. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr. Top. Med. Chem. 2:1239-1259.
45. Shikhaliev, K. S., A. V. Falaleev, G. I. Ermolova, and A. S. Solov'ev. 2002. 2-Quinazolylguanidines in heterocyclization reactions. 2. Condensation with α,β-unsaturated carbonyl compounds. Chem. Heterocycl. Compounds 38: 210-212.
46. Sindermann, H., and J. Engel. 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100:S17-S20.
47. Söntjens, S. H. M., J. T. Meijer, H. Kooijman, A. L. Spek, M. H. P. van Genderen, R. P. Sijbesma, and E. W. Meijer. 2001. A multiple hydrogenbond scaffold based on dipyrimidin-2-ylamine. Org. Lett. 3:3887-3889.
48. Tovar, J., S. Wilkinson, J. C. Mottram, and A. H. Fairlamb. 1998. Evidence that trypanothione reductase is an essential enzyme in Leishmania by targeted replacement of the tryA gene locus. Mol. Microbiol. 29:653-660.
49. Vyas, S. P., and S. Gupta. 2006. Optimizing efficacy of amphotericin B through nanomodification. Int. J. Nanomedicine 1:417-432.
50. Webb, T. R., D. Lvovskiy, S.-A. Kim, X. Ji, N. Melman, J. Linden, and K. A. Jacobson. 2003. Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors. Bioorg. Med. Chem. 11:77-85.
51. Werbovetz, K. A. 2000. Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis. Curr. Med. Chem. 7:835-860.
52. Wyllie, S., M. L. Cunningham, and A. H. Fairlamb. 2004. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem. 279:39925-39932.
53. Zhang, J.-H., T. D. Y. Chung, and K. R. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen. 4:67-73.
54. Zhang, Y., C. S. Bond, S. Bailey, M. L. Cunningham, A. H. Fairlamb, and W. N. Hunter. 1996. The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 Å resolution. Protein Sci. 5:52-61.